At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 239 enrolled
Drug / intervention
darbepoetin alfa +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa
In Brief
A Phase 2 clinical trial evaluating darbepoetin alfa, epoetin alfa, and 2 other interventions for Anemia and 6 related conditions. Completed, enrolled 239 participants across 1 site.
Detailed Summary
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer. PURPOSE: This randomized clinical trial is studying four different schedules of epoetin alfa or darbepoetin alfa to compare how well they work in treating patients with anemia caused by chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartMay 2007
Primary CompletionJun 2009
TodayJul 2026
First PostedDec 28, 2006
Enrollment StartMay 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.5 years ago
Interventions
darbepoetin alfadrug
epoetin alfadrug
fatigue assessment and managementprocedure
quality-of-life assessmentprocedure